Apotex Health Corp. made a strong entrance on the Toronto Stock Exchange on Wednesday, with shares trading at C$28 at the open - roughly 17% above the IPO price of C$24. The opening price places the company above the C$1.3 billion capital raised in the offering completed ahead of the listing and stands out as one of the more significant Canadian market debuts in recent memory.
The company priced an upsized sale of 54.2 million shares, producing gross proceeds of about C$1.3 billion. Of those proceeds, approximately C$850 million will flow to Apotex via a treasury-share issuance, while existing shareholders sold around C$450 million worth of stock in the secondary portion of the transaction. That split highlights a funding mix that combines fresh capital for the company with liquidity for prior investors.
Investors appear to be rewarding more than the size of the deal. Apotex reported a marked improvement in financial performance for the fiscal year ended March 31, posting revenue of $3.5 billion and net income of $374 million. That represents a significant turnaround from the prior fiscal year, when the company recorded revenue of $2.9 billion and a net loss of $147 million. The move to profitability is an observable shift in the company’s operating results over the last year.
The timing of the capital raise carries balance-sheet implications. Apotex reported total debt of $2.9 billion as of March 31. Management has stated that net proceeds from the treasury-share sale will be used to repay an $800 million term loan that is fully drawn. Executing that repayment would reduce drawn leverage tied to that specific facility and is positioned to improve the company’s financial flexibility.
Founded in 1974 by Barry Sherman, Apotex has expanded into the largest Canadian-based pharmaceutical company. Its operations span generic medicines, biosimilars, branded pharmaceuticals and consumer health products. The company serves markets across the Americas and operates in multiple jurisdictions, including the United States, Mexico and India.
Market participants noted that the listing offers a rare positive data point for Canada’s subdued IPO environment, signaling investor appetite for profitable healthcare platforms. The strong debut could influence other private companies that are evaluating the timing and structure of potential public offerings.
Contextual note: The facts above reflect the company’s stated financial results, the structure of the offering, and management’s declared use of proceeds. Where information is limited in the public disclosures, this report reflects only the available data without inference.